Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-567-0 | CAS number: 585-88-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / bone marrow chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- publication
- Title:
- The genotoxic and teratogenic effects of maltitol in rats
- Author:
- Semir Canimoglu and Eyyup Rencuzogullari
- Year:
- 2 012
- Bibliographic source:
- Toxicology and Industrial Health, 29 (10) 935-943
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 475 (Mammalian Bone Marrow Chromosome Aberration Test)
- Version / remarks:
- The assay design was based on OECD TG 475 version of 21 July 1997 with modifications.
Only 4 animals (2/sex) were used per dose (instead of 5 of one sex required) and higher doses than recomended were used.
Based on the 1997 version of OECD TG 475, the Intraperitoneal route was used for treatment and 100 metaphases/animal were evaluated in the current study.
However, since 1997, a new version of the OECD TG 475 is available (adopted in 29 July 2016). In the current guideline, intraperitoneal route is no more recommended and 200 metaphases should be evaluated instead of 100 analyzed in the 1997 version. - Deviations:
- yes
- Remarks:
- See above in "Version/remarks" section
- GLP compliance:
- no
- Type of assay:
- mammalian bone marrow chromosome aberration test
Test material
- Reference substance name:
- 4-O-α-D-glucopyranosyl-D-glucitol
- EC Number:
- 209-567-0
- EC Name:
- 4-O-α-D-glucopyranosyl-D-glucitol
- Cas Number:
- 585-88-6
- Molecular formula:
- C12H24O11
- IUPAC Name:
- 4-O-α-D-glucopyranosyl-D-glucitol
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: from Sigma, Batch No. M8892
- Expiration date of the lot/batch: not detailed
- Purity test date: no detailed
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: not specified
- Stability under test conditions: not specified
- Solubility and stability of the test substance in the solvent/vehicle: not specified
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: not applicable
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
Maltitol was dossilved in distilled water, no more details.
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Medical Sciences, Experimental Research and Application Centre of Cukurova university
- Age at study initiation: 12-16 weeks old
- Weight at study initiation: 187.45±1.22g
- Assigned to test groups randomly: not detailed
- Fasting period before study: not detailed
- Housing: Plastic cages (32x46x10 cm)
- Diet (e.g. ad libitum): not detailed
- Water (e.g. ad libitum): not detailed
- Acclimation period: not detailed
ENVIRONMENTAL CONDITIONS
Not detailed
IN-LIFE DATES: Not detailed
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- - Vehicle(s)/solvent(s) used: Distilled water
- Justification for choice of solvent/vehicle: no justification provided
- Concentration of test material in vehicle: not specified
- Amount of vehicle (if gavage or dermal): not applicable
- Type and concentration of dispersant aid (if powder): not detailed
- Lot/batch no. (if required): not specified - Details on exposure:
- The rats were intraperitoneally treated with 2.5, 5 and 10 g/kg body weight (bw) concentrations of maltitol.
- Duration of treatment / exposure:
- 6, 12 and 24 h treatment periods.
- Frequency of treatment:
- Single administration
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 other: g/kg body weight
- Dose / conc.:
- 2.5 other: g/kg body weight
- Dose / conc.:
- 5 other: g/kg body weight
- Dose / conc.:
- 10 other: g/kg body weight
- No. of animals per sex per dose:
- Four rats were used per dose (2 males and 2 females)
- Control animals:
- yes
- yes, concurrent vehicle
- Positive control(s):
- Ethyl-Carbamate Urethane
- Justification for choice of positive control(s): not specified
- Route of administration: intraperitoneal route
- Doses / concentrations: 0.4 g/kg bw
Examinations
- Tissues and cell types examined:
- Femur bone marrow was sampled for each animal and metaphases were isolated in order to be assessed.
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: no justification was provided
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields):
The rats were intraperitoneally treated with 2.5, 5 and 10 g/kg body weight (bw) concentrations of maltitol for 6, 12 and 24 h treatment periods.
DETAILS OF SLIDE PREPARATION:
In order to arrest mitosis, colchicine (1 mg/kg bw, Sigma C9754) was injected intraperitoneally 2 h before the animals were killed by cervical dislocation. The femurs were stripped proximally,
and the bone marrow was aspirated in 4 ml of 0.9%NaCl (37°C). The suspension was centrifuged for 10 min at 1200 r/min, and the obtained bone marrow pellet was resuspended in 0.4%KCl at 37°C for 5 min and then fixed in cold methanol glacial acetic acid (3:1) for 20 min at room temperature. The treatment with a fixative was repeated two times. Then, the cells were spread on glass slides and air-dried. The slides were stained with Giemsa (5% in Sorensen buffer)for 15 min.
METHOD OF ANALYSIS:
One hundred well-spread metaphases per animal (totally 400 metaphases per group)were examined at 1000Xmagnification for the occurrence of the structural and numerical CA. The mitotic index (MI) was also determined by scoring 3000 cells fromeach animal.
- Statistics:
- The t test was used for the statistical significance of the percentage of abnormal cells, the structural and total CA and MI. Dose–response relationships were
determined from the correlation and regression coefficients of the percentage of abnormal cells, structural and total Chromosomes Aberrations and Mitotic Index.
Results and discussion
Test results
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Maltitol did not induce the percentage of abnormal cells and the structural CAs in all the concentrations and treatment periods. In addition, maltitol did not decrease the MI, so it had no cytotoxic effect in the bone marrow cells of rats.
There was no dose-dependent effect in all the tested parameters. Maltitol did not cause numerical chromosome abnormalities.
Any other information on results incl. tables
Table1.The percentage of abnormal cells,structural chromosome aberrations and the MI in rat bone marrow cells treated with maltitol.
Test substance |
Periods (hours) |
Concentrations (g/kgbw) |
Abnormalities B' |
Abnormalitie B'' |
Percent of abnormal cells± SE |
Structural CA ± SE(%) |
Mitosis index ± SE (%) |
Control |
– |
– |
1 |
4 |
1.00+0.40 |
1.25+0.47 |
3.66+0.13 |
Urethane |
6 |
0.4 |
6 |
27 |
7.75+1.79 |
8.25+1.93 |
3.16+0.43 |
Maltitol |
6 |
2.5 |
6 |
1 |
1.50+0.64 |
1.75+0.75 |
4.81+0.58 |
|
6 |
5 |
2 |
5 |
1.25+0.47 |
1.75+0.75 |
4.37+0.53 |
|
6 |
10 |
6 |
2 |
2.00+0.70 |
2.00+0.70 |
5.37+0.13 |
Urethane |
12 |
0.4 |
14 |
15 |
6.75+1.43 |
7.25+1.54 |
4.65+0.52 |
Maltitol |
12 |
2.5 |
8 |
4 |
2.75+0.85 |
3.00+0.81 |
4.29+0.69 |
|
12 |
5 |
6 |
3 |
2.00+0.70 |
2.25+0.75 |
5.30+0.40 |
|
12 |
10 |
1 |
4 |
1.00+0.40 |
1.25+0.62 |
5.39+0.48 |
Urethane |
24 |
0.4 |
7 |
34 |
8.25+1.10 |
10.25+1.65 |
3.44+0.46 |
Maltitol |
24 |
2.5 |
8 |
6 |
3.00+0.91 |
3.50+1.04 |
4.20+0.50 |
|
24 |
5 |
5 |
1 |
1.50+0.28 |
1.50+0.28 |
4.79+0.51 |
|
24 |
10 |
6 |
4 |
2.25+1.03 |
2.50+1.19 |
3.68+0.23 |
MI: mitotic index; CA: chromosome aberration; SE: standard error. |
|||||||
aStructuralchromosomal aberrations: B': chromatid type, B'': chromosome type abnormalities. |
Applicant's summary and conclusion
- Conclusions:
- Under the experimental conditions of the study, Maltitol, when administered to rats by intraperitoneal route, did not induce chromosome aberrations or cytotoxic effect on bone marrow cells. hence, the maltitol was negative in a chromosome aberration test in vivo.
- Executive summary:
In this non GLP compliant study, the genotoxic and cytotoxic effects of the maltitol were investigated in the bone marrow cells of rats using the chromosome aberration (CA) test, according to method similar to OECD 475 guideline.
To reveal the genotoxicity and cytotoxicity of maltitol, rats were intraperitoneally administered 2.5, 5 and 10 g/kg body weight (bw) concentrations of maltitol for 6, 12 and 24 h treatment period. Ethyl carbamate was used as positive control condition. Colchicine was used and administered to rats 2 hours before sacrifice in order to arrest mitosis. After treatment, femurs were sampled and bone marrow prepared in order to evaluate the chromosome aberrations and mitotic index.
Maltitol did not induce the percentage of abnormal cells and the structural CAs in all the concentrations and treatment periods. In addition, maltitol did not decrease the MI, so it had no cytotoxic effect in the bone marrow cells of rats. There was no dose-dependent effect in all the tested parameters. Maltitol did not cause numerical chromosome abnormalities.
Under the experimental conditions of the study, Maltitol, when administered to rats by intraperitoneal route, did not induce chromosome aberrations or cytotoxic effect on bone marrow cells. hence, the maltitol was negative in a chromosome aberration test in vivo.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.